Quinoline antimalarials cause
drug-induced electrocardiographic QT prolongation, a potential risk factor for
torsade de pointes. The effects of currently used
antimalarials on the electrocardiogram (ECG) were assessed in pregnant women with
malaria. Pregnant women with microscopy-confirmed
parasitemia of any
malaria species were enrolled in an open-label randomized controlled trial on the Thailand-Myanmar border from 2010 to 2016. Patients were randomized to the standard regimen of
dihydroartemisinin-
piperaquine (DP) or
artesunate-
mefloquine (ASMQ) or an extended regimen of
artemether-lumefantrine (AL+). Recurrent Plasmodium vivax
infections were treated with
chloroquine. Standard 12-lead electrocardiograms were assessed on day 0, 4 to 6 h following the last dose, and day 7. QT was corrected for the heart rate by a linear mixed-effects model-derived population-based correction formula (QTcP = QT/RR0.381). A total of 86 AL+, 82 ASMQ, 88 DP, and 21
chloroquine-treated episodes were included. No patients had an uncorrected QT interval nor QTcP of >480 ms at any time. QTcP corresponding to peak
drug concentration was longer in the DP group (adjusted predicted mean difference, 17.84 ms; 95% confidence interval [CI], 11.58 to 24.10; P < 0.001) and
chloroquine group (18.31 ms; 95% CI, 8.78 to 27.84; P < 0.001) than in the AL+ group, but not different in the ASMQ group (2.45 ms; 95% CI, -4.20 to 9.10; P = 0.47) by the multivariable linear mixed-effects model. There was no difference between DP and
chloroquine (P = 0.91). QTc prolongation resulted mainly from widening of the JT interval. In pregnant women, none of the
antimalarial drug treatments exceeded conventional thresholds for an increased risk of
torsade de pointes.